Baird analyst Jack Allen lowered the firm’s price target on MiNK Therapeutics (INKT) to $4 from $8 and keeps an Outperform rating on the shares. The firm said the company announced 3Q24 financials and provided pipeline updates, which were generally in line with expectations.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks